Start Over

Favipiravir use in children with COVID-19 and acute kidney injury: is it safe?

Authors :: Ozsurekci Y
Oygar PD
Gürlevik SL
Kesici S
Ozen S
Kurt Sukur ED
Gülhan B
Topaloglu R
Bayrakci B
Cengiz AB
Source :: Pediatric nephrology (Berlin, Germany) [Pediatr Nephrol] 2021 Nov; Vol. 36 (11), pp. 3771-3776. Date of Electronic Publication: 2021 May 22.
Publication Year :: 2021
Abstract: Background: The rising number of infections due to Severe Acute Respiratory Syndrome Coronavirus-2 (popularly known as COVID-19) has brought to the fore new antiviral drugs as possible treatments, including favipiravir. However, there is currently no data regarding the safety of this drug in patients with kidney impairment. The aim of this paper, therefore, is to share our experience of the use of favipiravir in pediatric patients affected by COVID-19 with any degree of kidney impairment.<br />Methods: The study enrolled pediatric patients aged under 18 years and confirmed as suffering from COVID-19 and multisystem inflammatory syndrome in children (MIS-C) with any degree of kidney injury, who were treated with favipiravir at the time of admission.<br />Results: Out of a total of 11 patients, 7 were diagnosed with MIS-C and 4 with severe COVID-19. The median age of the cases was 15.45 (9-17.8) years and the male/female ratio was 7/4. At the time of admission, the median serum creatinine level was 1.1 mg/dl. Nine patients were treated with favipiravir for 5 days, and 2 patients for 5 days followed by remdesivir for 5-10 days despite kidney injury at the time of admission. Seven patients underwent plasma exchange for MIS-C while 2 severely affected cases underwent continuous kidney replacement therapy (CKRT) as well. One severe COVID-19 patient received plasma exchange as well as CKRT. Serum creatinine values returned to normal in mean 3.07 days.<br />Conclusions: Favipiravir seems a suitable therapeutic option in patients affected by COVID-19 with kidney injury without a need for dose adjustment.<br /> (© 2021. IPNA.)